Clinical Trial Update: An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort [Phase 1]

View source ↗

Summary

An open-label, long-term extension study assessed the safety and tolerability of deflazacort in Duchenne Muscular Dystrophy; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• DEFLAZACORT (Deflazacort)
• EMFLAZA (deflazacort)

Snippet

Sponsor: PTC Therapeutics | Conditions: Duchenne Muscular Dystrophy | Phase 1 | Status: COMPLETED